Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series

Drug-induced interstitial lung disease (DI-ILD) is a rare adverse event associated with targeted therapies that inhibit the anaplastic lymphoma kinase (ALK) protein. Although newer-generation ALK inhibitors such as alectinib significantly improve survival in metastatic ALK-rearranged non-small cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Myall, Nathaniel J., Lei, Amy Q., Wakelee, Heather A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867755/
https://www.ncbi.nlm.nih.gov/pubmed/33569330
http://dx.doi.org/10.21037/tlcr-20-564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867755/
https://www.ncbi.nlm.nih.gov/pubmed/33569330
http://dx.doi.org/10.21037/tlcr-20-564

Ejemplares similares